Gluliptin Duo Tablet 2.5/850 mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.
MFDS item code 202002091 · Approved 2020.03.25
This product's status changed to Expired on 2025.03.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood sugar control in adult patients with type 2 diabetes. It is administered as an adjunct to diet and exercise therapy and can also be used for individuals who have not previously received diabetes medication treatment. Additionally, it is used in cases where sufficient blood sugar control is difficult with monotherapy of metformin or combination therapy of linagliptin and metformin. For patients who struggle with blood sugar control even when combined with maximum doses of metformin and sulfonylureas or insulin, this medication can be used to enhance efficacy. It can also be used in conjunction with empagliflozin to assist with blood sugar control in cases where blood sugar control remains difficult. Overall, this medication is utilized in various scenarios to enhance blood sugar control.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients in whom adequate glycemic control cannot be achieved with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients in whom adequate glycemic control cannot be achieved with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia. 5. Patients in whom adequate glycemic control cannot be achieved with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication is primarily used for the treatment of type 2 diabetes and helps with blood sugar control. However, it should not be administered to certain patients. For example, patients who are allergic to any components of this medication, have type 1 diabetes, lactic acidosis, diabetic ketoacidosis, diabetic coma, or who have severe renal impairment should not use it. Additionally, it should not be given in cases of acute diseases that may affect renal function such as dehydration, severe infections, acute trauma, shock, or acute myocardial infarction. Patients with reduced liver function, severe gastrointestinal disorders, acute alcohol intoxication, very poor nutritional status, or pregnant or breastfeeding women should also avoid using this medication. When using this medication, caution regarding hypoglycemic symptoms is advised, especially when taken with sulfonylureas or insulin, as there may be an increased risk of hypoglycemia necessitating dosage adjustments. Lactic acidosis, a severe side effect, can occur rarely, so if symptoms such as abdominal pain, muscle weakness, or respiratory distress occur, immediate consultation with a physician is needed. Elderly patients with compromised renal function or conditions that can alter renal function should regularly undergo renal function tests. Patients with compromised cardiac function should also periodically monitor heart and kidney status when using this medication. This medication should be temporarily discontinued before and after examinations using radiopaque iodine contrast agents, and patients scheduled for surgery should also discontinue it prior to surgery and restart it after kidney function has recovered postoperatively. Rare side effects such as pancreatitis or blistering similar to pemphigoid may occur during treatment, so if severe abdominal pain or skin abnormalities develop during use, immediate consultation with medical personnel is advised. Long-term use may lower vitamin B12 levels, thus an evaluation of vitamin B12 levels and supplementation may be necessary if anemia or neurological symptoms occur. It is recommended that women who are pregnant or planning to become pregnant avoid using this medication, and it is also advised not to use it while breastfeeding. This medication is not recommended for children under 10 years of age or adolescent patients, as safety and efficacy have not been established for this demographic. Elderly patients should periodically evaluate renal function when using this medication since renal impairment is common, and it should be administered at the minimal effective dose. In case of overdose, there is a risk of lactic acidosis, and immediate hospital treatment is necessary, possibly requiring hemodialysis. This medication should be stored away from moisture in a tightly sealed container, and it is advisable not to transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is best kept at room temperature between 1 to 30 degrees Celsius, avoiding extremes of heat or cold.
Biconvex oval film-coated tablet in bright orange
60 tablets/box [(10 tablets/PTP*6)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.